Program
AMO959
A development code. Also written as “BY101298 Capsules”.
In Novartis's pipeline, DNA PK inhibitor
. Its studies are mostly in Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chengdu Baiyu Pharmaceutical | 11 open or running | phase 1since Jun 12, 2024 | Jun 12, 2024 | none ahead |
| Novartis | 11 open or running | phase 2since Nov 7, 2025 | Nov 7, 2025 | Jul 10, 2028phase 2 · NCT07226986 |
- Named in Novartis’s own pipeline as
AMO959
, phase 1, as of Nov 16, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 12, 2024First study: phase 1 study in Solid Tumor, AdultNew to Chengdu Baiyu PharmaceuticalChengdu Baiyu Pharmaceutical · NCT06462716 · 36 enrolled · China
- Nov 7, 2025Novartis's first study: phase 2 study in PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based ChemotherapyNew to NovartisNovartis · NCT07226986 · 123 planned · United States, Australia, France and more
Ahead
- Jul 10, 2028Primary completion: phase 2 study in PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based ChemotherapyNovartis · NCT07226986
TargetBeta
“DNA PK inhibitor”the company's pipeline, read by Claude · source
Other programs on PRKDC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| bosmolisibrule | Boryung Pharmaceutical | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy · United States, Australia, France and more | 2 | Recruiting | Novartis | Jul 10, 2028 | 123 |
| NCT06462716Solid Tumor, Adult · China | 1 | Active, not recruiting | Chengdu Baiyu Pharmaceutical | Dec 31, 2024 | 36 |
How it is read
Names in the registry
- “AMO959”, 1 entry
- “BY101298 Capsules”, 1 entry
Codes read as this program: AMO959, BY101298.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.